FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Changes Coming to HRT Boxed Warning: Makary

FDA commissioner Martin Makary says on a CNN podcast that changes should soon be announced to a Boxed Warning on some hormone replacement therapy prod...

latest-news-card-1
Human Drugs

FDA Grants Fast Track for Alzheimers Drug

FDA grants Bristol Myers Squibb fast-track status for its investigational Alzheimers therapy BMS-986446.

Human Drugs

FDA Touts Sentinel Successes

FDA issues a report highlighting Sentinel System activities and achievements between 2022 and 2024.

latest-news-card-1
Human Drugs

FDA, Vanda Agree on Dispute Actions

FDA and Vanda agree to a series of actions to resolve their disputes over the companys Hetlioz and tradipitant.

latest-news-card-1
Medical Devices

CDRH Learn Module on Quality Management System

A CDRH Learn module reviews the Quality Management System Regulation requirements for medical device manufacturers and the benefits that flow from fol...

latest-news-card-1
Human Drugs

17 New, 64 Revised Product-Specific Guidances

FDA issues 17 new and 64 revised product-specific guidances to aid in developing generic drugs.

latest-news-card-1
Human Drugs

Umoja Bio Wins Fast Track for B-Cell Malignancies Drug

FDA grants Umoja Biopharma a fast track designation for its investigational therapy UB-VV111 for treating relapsed or refractory large B-cell lymphoma...

latest-news-card-1
Human Drugs

FDA Complete Response on Menkes Disease Drug

FDA issues a complete response letter to Fortress Biotech and its majority-owned subsidiary, Cyprium Therapeutics, regarding their Menkes disease drug...

latest-news-card-1
Human Drugs

FDA Approves Novartis Rhapsido for Urticaria

FDA approves a Novartis NDA for Rhapsido (remibrutinib), a Brutons tyrosine kinase inhibitor for treating adults with chronic spontaneous urticaria.

latest-news-card-1
Medical Devices

CDRH Proposing 11 Guidances for FY 2026

CDRH releases a list of 11 final and draft guidances it plans to issue in FY 2026 if resources permit.